Individuals Coming Off Anti-Obesity Injections Gain Back Pounds at a Quadrupled Rate Than Dieters
Fresh analysis reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop conventional lifestyle programs.
Research printed in a leading health publication demonstrates that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing such medications need to be cognizant of the potential of quick weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of recovery implies a return to starting mass within about one and a half years.
Analyzing Treatments
The research, which examined 37 of studies involving thousands of patients, contrasted the outcomes of the injectable medications with older methods.
The team emphasize that people who shed pounds through dieting typically see a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Understanding the Quick Regain
Experts suggest the mechanism of the drugs explains the heightened weight return.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement means appetite is unsuppressed, making excessive eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, due to the high risk of relapse, the therapy should be considered long-term.
This view is echoed by pharmaceutical companies, who note that the results "highlight the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the medication report a powerful resurgence of cravings.
"I experienced a switch that goes on and I was suddenly starving," recalled a patient.
This difficulty is worsened if patients have not established lasting lifestyle or habit changes during therapy.
Growing Interest
Recent estimates suggest that millions of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, experts emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone cure and maintained weight loss relies on integrated behavioural support.